vialroom

#retatrutide 2025-06-15

Sunday26 messages7 participantstimes are UTC
Highlights from this day
  • sunday_shot — held at 12 for 15 months and it never plateaued for me, which i cant explain 00:45
  • ghent_gradient — stepping in 10 increments instead of doubling is the only thing i would change if i started again 02:43
  • marrow.mod — people insist on small steps because the side effects arrive faster than on the other two 03:32
  • hard_stop_hal — is TRIUMPH the phase 3 programme 03:59
SS

held at 12 for 15 months and it never plateaued for me, which i cant explain

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)
TO

energy expenditure isnt something i could feel, though my sleep tracker disagreed with me

GG

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me

reconstituted the 30 vial to 4mg/ml specifically so i could take 0.25 without measuring crumbs

stepping in 10 increments instead of doubling is the only thing i would change if i started again

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)

anyone tracking blood pressure alongside the heart rate

02:48marrow.mod pinned a message
WV

while im here triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history

people insist on small steps because the side effects arrive faster than on the other two

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
👀9🧊5
TO

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

🧊9📈1
HS

Medutest came back 98.1 on one lot and 99.4 on the next from the same GGPeps, both fine

TO

how do people square the research use only framing with logging their own use